Story · Medicine & Biotech

Lp(a) HORIZON trial: Lp(a) fell by 78%, but cardiovascular outcomes unexpectedly neutral

1 outlet · first reported by AHA Newsroom 4d ago

Coverage, in order

  1. 4d ago
    AHA Newsroom indie study randomized trialn=8,300
    Lp(a) HORIZON trial: Lp(a) fell by 78%, but cardiovascular outcomes unexpectedly neutral

    Research Highlights: In the 7-year, phase III, multicenter, international Lp(a) HORIZON trial, the novel medication pelacarsen lowered Lp(a) levels by a mean of 78% in a trial with more than 8,300 adults with cardiovascular disease in 42 countries. ...

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.